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ABSTRACT
Background: Cell lines provide a powerful model to study cancer and here we 
describe a new spontaneously immortalised epithelial ovarian cancer cell line (NUOC-1)  
derived from the ascites collected at a time of primary debulking surgery for a mixed 
endometrioid / clear cell / High Grade Serous (HGS) histology.
Results: This spontaneously immortalised cell line was found to maintain 
morphology and epithelial markers throughout long-term culture. NUOC-1 cells grow 
as an adherent monolayer with a doubling time of 58 hours. The cells are TP53 
wildtype, positive for PTEN, HER2 and HER3 expression but negative for oestrogen, 
progesterone and androgen receptor expression. NUOC-1 cells are competent in 
homologous recombination and non-homologous end joining, but base excision repair 
defective. Karyotype analysis demonstrated a complex tetraploid karyotype. SNP array 
analysis of parent and derived subpopulations (NUOC-1-A1 and NUOC-1-A2) cells 
demonstrated heterogeneous cell populations with numerous copy number alterations 
and a pro-amplification phenotype. The characteristics of this new cell line lends it to 
be an excellent model for investigation of a number of the identified targets. 
Materials and Methods: The cell line has been characterised for growth, drug 
sensitivity, expression of common ovarian markers and mutations, clonogenic 
potential and ability to form xenografts in SCID mice. Copy number changes and 
clonal evolution were assessed by SNP arrays.
INTRODUCTION
Epithelial ovarian cancer is often described as 
the silent killer due to absence of symptoms and late 
presentation. This combined with the lack of specific 
sensitive markers and techniques for screening leads to 
diagnosis at late disease stage in more than 70% of patients. 
Ovarian cancer is the leading cause of gynaecological 
cancer mortality worldwide [1] and despite much research 
into the treatment of ovarian cancer the overall mortality 
has changed little over the past 20 years with a 5-year 
overall survival of 30–39% [2]. It has long been recognised 
by clinicians that ovarian cancer is a set of heterogeneous 
diseases but, despite this, ovarian carcinoma continues to 
be treated clinically as a single disease using a combination 
of debulking surgery and platinum-based chemotherapy. 
The observed variation in the clinical behaviour of ovarian 
cancer alongside the growing data reporting molecular 
heterogeneity suggests that a heterogeneous in vitro model 
for the study of ovarian cancer is long overdue. 
Established cell lines provide an invaluable tool for 
studying biological functions at the molecular and cellular 
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level. Existing human ovarian cancer cell lines possess 
the advantage of high proliferative capacity, clonogenicity 
and extended life span in culture. However, ovarian cancer 
cell lines have rarely been derived from chemotherapy-
naive patients, many were established following viral 
transformation, such as with SV40 Large T antigen or 
xenograft passaged in immunocompromised mice [3–6]. 
Very few cell lines are derived from mixed histology 
tumours and with this type of tumour being less common, 
reliable models for the study of mixed histology tumours 
are needed. Additionally, there is evidence to suggest 
that many cell lines contain significant misidentification, 
duplication, and loss of integrity [7] making new well 
characterised models desirable. 
In this study, we describe a new ovarian cancer cell 
line derived from ascites of a chemotherapy-naïve patient. 
The molecular and growth characteristics of this cell line 
present unique features, thereby providing the research 
community with a new tool in the study of different 
aspects of mixed histology ovarian cancer. 
RESULTS
Molecular characterization of NUOC-1 cell line
The NUOC-1 cell line was derived from ascites of 
a chemotherapy naive patient. The female patient was 
of Caucasian background and 62 years old when she 
presented with disseminated intraabdominal malignancy. 
She underwent primary surgery with optimal cytoreduction 
(with residual milliary disease over the diaphragms and 
small bowel mesentery). Ascites was collected at the time 
of surgery for culture. Final histology confirmed FIGO 
Stage IIIc high grade mixed ovarian carcinoma of the 
right ovary which was 80% endometrioid, 15% clear cell 
and 5% high grade serous (HGS) carcinoma. Repeat CT 
imaging demonstrated new liver and peritoneal metastases 
and she died of progressive disease 52 days post-op after 
only 1 cycle of carboplatin. She did not have any known 
relevant familial history for cancer predisposition. 
Bright light microscopy revealed a cobblestone 
morphology characteristic of epithelial cells which was 
maintained during repeated passage (Figure 1A). The 
growth of NUOC-1 was initially slow with a 128 hour 
doubling time, but with continued culture this stabilised 
to 58 hours. NUOC-1 formed colonies when grown on 
plastic at an efficiency of 2.2% +/− 0.6%. NUOC-1 cells 
stained positive for proteins characteristic of epithelial 
ovarian carcinoma (pancytokeritin, epithelial cell adhesion 
molecule (EpCAM), epithelial related antigen MOC31 
and cancer antigen 125 (CA125)) and negative for germ 
cell related antigen D240 and Vimentin (Figure 1B–1F). 
NUOC-1 cells did not express oestrogen, progesterone 
and androgen receptors (Figure 2A), but expressed the 
receptor tyrosine-protein kinase erbB-3 (HER-3) receptor 
and the receptor tyrosine-protein kinase erbB-2 (HER-2) 
receptor at a higher level than LNCAP and SKOV-3 cell 
line controls (Figure 2A). Sequencing of the entire coding 
region of BRCA1, BRCA2 and phosphatase and tensin 
homologue deleted on chromosome 10 (PTEN) revealed no 
germline or somatic mutations. Furthermore PTEN protein 
expression was confirmed by western blotting (Figure 2B).
Figure 1: Phenotypic appearances of NUOC-1 cells. (A) Brightfield demonstrating cobblestone monolayer (20x magnification); 
immunoflourescent images (40x magnification) with antibodies targeted against: (B) Alexafluor 596 anti-CA125; (C) FITC-anti-
pancytokeratin; (D) Alexflour 488 anti-EpCAM; (E) Alexafluor 596 anti-MOC 31; (F) Alexaflour 596 anti-Vimentin.
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P53 function assessment
Dysregulated tumour protein p53 is recognised as 
a characteristic feature of HGS. To determine if the small 
proportion of the HGS within NUOC-1 immortalised, 
p53 status was determined. Sanger dideoxy sequencing 
of TP53 Exons 3-9 detected no mutations. Consistently 
with functional p53, treatment with Mouse double 
minute 2 homolog (MDM2)-p53 antagonist (Nutlin-3) 
demonstrated accumulation of MDM2 in NUOC-1 cells 
concomitant with a dose dependent increase in p53 and 
cyclin-dependent kinase inhibitor 1 (p21) protein levels 
(Figure 3A). In contrast, Nutlin-3 treatment of CP70 cells 
did not significantly induce p53 or p21, consistent with the 
established TP53 mutation in this cell line. Nutlin-3 had a 
greater growth inhibitory effect in TP53 wild-type NUOC-1 
cells compared to TP53 mutant CP70 cells (GI50 0.7 µM +/-
0.03 µM vs 23.5 µM +/−0.9 µM; p < 0.00001, Figure 3B). 
DNA repair assessment
DNA repair ability of NUOC-1 cells was assessed 
by validated functional assays and sequencing of DNA 
repair genes. A greater than two fold increase in γH2AX 
and RAD51 foci formation following exposure to IR is 
used as a cut off to define homologous recombination 
(HR) competence and a < 2 fold increase in RAD51 
is classed as HR deficient [8, 9]. NUOC-1 cells were 
deemed HR competent with a 2.84 fold rise in RAD51 
foci, compared to untreated controls (Figure 4A). Non 
homologous end joining (NHEJ) function is assessed by 
the ability of cell extracts to rejoin incompatible vector 
DNA ends correctly. NUOC-1 cells were found to be 
NHEJ competent as evidenced by the ability to rejoin 
both compatible and incompatible DNA breaks correctly 
(Figure 4B). Excess production of 8-OHdG inferred 
the non-functioning of base excision repair  (BER) and 
was quantified by competitive ELISA in NUOC-1 cells 
(Figure 4C). AA8 (BER competent) with its derivative 
EM9 cell lines (BER deficient due to XRCC1 mutation) 
were used as positive and negative controls. NUOC-1 cell 
8-OHdG level was 4.0 nM +/- 0.64 nM, indicating that 
NUOC-1 cells were BER defective (Figure 4C). Massively 
parallel sequencing identified heterozygous mutations in 
OGG1, WRN, NBN and NEIL3, and homozygous mutation 
were identified in ERCC5 (Figure 4D). 
Drug sensitivity assessment
Sensitivity to common therapeutics was assessed 
by SRB growth inhibition assays and compared to 
BRCA1 mutant HGSC cell line, UWB1-289 and for 
assessment of toxicity to normal tissue, a cell line 
derived from normal ovarian surface epithelium (OSEC-
2). NUOC-1 cell line was significantly more resistant to 
rucaparib compared to UWB1.289 cells (p < 0.0001, 
Figure 2: Receptor expression in NUOC-1 cell line assessed by western blotting. (A) Tyrosine and endocrine receptor 
expression in the NUOC-1 cell line. NUOC-1 cells express the Her-3 receptor (positive control MCF7) and overexpress the Her-2 receptor 
(positive control LNCAP and SKOV-3). NUOC-1 cells do not express the oestrogen receptor (positive control MCF7), the progesterone 
receptor (positive control MCF7) or the androgen receptor (positive control LNCAP). (B) PTEN expression levels in NUOC-1 cells 
demonstrated by Western blot analysis. LNCAP and PC3 cells serve as negative controls whilst OSEC-2 is a positive control. Blots are 
representative of three independent experiments. 
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Table 1), with GI50 similar to OSEC-2 cells. NUOC-1 
cells were also significantly more resistant to cisplatin 
when compared to UWB1.289 (p < 0.0001, Table 1), but 
more sensitive than OSEC-2 cells (p = 0.001, Table 1). 
Compared to the OSEC2 cell line, NUOC-1 was more 
sensitive to camptothecin (p < 0.0001, Table 1), no 
significant difference was noted when compared to 
UWB1.289 cells. NUOC-1 cells were more resistant 
to Paclitaxel compared to OSEC-2 cells (p = 0.017, 
Table  1 ) and UWB1.289 cells (p = 0.007, Table 1). In 
contrast, there was no significant difference between 
NUOC-1, UWB1.289 and OSEC2 in terms of sensitivity 
to doxorubicinor irradiation (Table 1). 
Clonal evolution and copy number alterations
NUOC-1 cells revealed a complex, near-tetraploid 
karyotype, with loss of chromosomes 3,6,11,16 and 19, 
and structural abnormalities including rearrangements of 
5q, 9q, 17p and 18q (Figure 5). 
To assess clonal evolution two NUOC-1 
subpopulations were derived. NUOC-1 cells were split 
Table 1: Sensitivity to cytotoxic agents in NUOC-1 cells compared to UWB1.289 and OSEC2 
cell line
Cytotoxic agent Mean GI50 and 95% confidence interval
NUOC-1 UWB1-289 F test p = OSEC-2 F-test p =
Cisplatin (µM) 1.24
0.93 to 1.66
0.12
0.07 to 0.22
< 0.0001 2.46
1.78 to 3.39
0.001
Paclitaxel (nM) 217.1
154.3 to 305.4
54.17
47.75 to 61.45
0.007 97.93
72.97 to 131.0
0.017
Camptothecin (nM) 15.85
9.10 to 27.63
6.98
3.04 to 16.03
0.59 171.0
103.0 to 283.8
< 0.0001
Doxorubicin (nM) 38.83
31.77 to 47.46
27.37
16.28 to 46.03
0.66 37.68
28.73 to 49.41
0.87
Rucaparib (µM) 6.18
4.69 to 8.15
0.62
0.31 to 1.23
< 0.0001 5.31
3.91 to 7.21
0.16
Irradiation (Gys) 3.55
2.43 to 5.18
2.69
1.65 to 4.37
0.94 4.94
3.25 to 7.49
0.21
Results are mean GI50 and 95% CI in µM or nM assessed by SRB assay. Results are the average of 3 independent experiments 
with 6 experimental repeats in each. Results were compared using comparison of fits for non linear regression, with Bonferroni 
correction for multiple comparisons. 
Figure 3: p53 function in NUOC1 cells. (A) Activation of MDM2, p53 and p21 protein in response to Nutlin3 treatment assessed by 
western blotting. Images are representative of 3 independent experiments. (B) Growth inhibition induced by Nutlin3 treatment in NUOC-1 
cell line assessed by SRB assay. The inhibition in NUOC-1 is compared to p53 wild type A2780 and p53 mutant CP70 cell lines. Results 
are the average of 3 independent experiments repeats. Error bars are SEM.
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at passage 4 and either grown continuously to passage 
14 (NUOC-1-A1) or frozen and stored in liquid nitrogen 
for 12 months before being thawed and also grown to 
passage 14. Short tandem repeat (STR) profiling of the 
parental NUOC-1 cells and the two sub-clones show that 
all three cell lines have identical profiles at 8 independent 
STRs (Supplementary Table 1). 
Intra-chromosomal copy number alterations 
deviating from the baseline copy number state 
(tetrapoloid) were identified in NUOC-1-A1, 
NUOC-1-A2 and parental NUOC-1 cells using 
OmniExpressExomeBeadChip genotyping data. NUOC-
1-A1 and NUOC-1-A2 carried numerous common copy 
number alterations, consistent with a shared recent 
ancestry (Supplementary Table 2). However, each cell 
line also carried a small number of unique copy number 
alterations not seen in the other cell line, indicating 
ongoing genomic evolution. Greater than 95% of copy 
number alterations were gains, with an average amplicon 
size of 2.6 Mb and 1.2 Mb in NUOC-1-A1 and NUOC-
1-A2, respectively. The vast majority of copy number 
alterations shared by NUOC-1-A1 and NUOC-1-A2 
were also visible in parental NUOC-1 cells. With regard 
to the unique copy number alterations, NUOC-1-A1 
has a low level copy number gain affecting the long 
arm and some of the short arm of chromosome 8 that is 
not seen in NUOC-1-A2. However, NUOC-1-A2 has a 
complex high level amplification on chromosome 8 that 
captures the MYC locus (Figure 6), and which is present 
in the dominant clone. Other genes implicated in type I 
ovarian cancer pathogenesis are also affected by copy 
number alterations in NUOC-1-A1 and/or NUOC-1-A2 
Figure 4: DNA repair capacity of NUOC-1 cell line. (A) Homologous recombination function assessed by RAD51 foci formation 
after 24 hour treatment with 10 µM Rucaparib compared to DMSO controls assessed by immunofluorescence. Fold rise in RAD51 foci 
in control and treated samples. Results are the average of foci counted across 3 separate microscopic fields of view counting > 50 cells in 
each. Error bars are SD. (B) Non homologous end joining function assessed by NUOC-1 cell extracts ability to rejoin linearised vectors 
into multimers. Images are agarose gels stained with GelRed. DNA-PK mutated M059J cells were used as negative control and DNA-PK 
competent M059J-FUS-1 cells were used as positive controls for end joining. Images are representative of 3 experimental repeats. (C) Base 
excision repair of NUOC-1 assessed by competitive ELISA. Results are the measurement of 8-OHdG levels. AA8 (BER proficient) cell 
line was used as positive control, EM9 (BER deficient) cell line was used as a negative control. (D) Summary of genetic data. The putative 
pathogenic variants (known mutations or variants with a population frequency of < 1 : 1000) are shown.
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(Figure 7A–7F). For example, the HINF1B and ERBB2 
genes are captured by amplicons of 405Kb and 115Kb, 
respectively, on chromosome 17 in both NUOC-1-A1 
and NUOC-1-A2. Likewise, the AKT1 gene is captured 
by a 155Kb amplicon on chromosome 14. The ARID1A 
gene is captured by a large region of copy neutral loss of 
heterozygosity on chromosome 1. 
Assessment of MYC amplification
Fluorescence in situ hybridization (FISH) for MYC 
copy number was carried out in samples at four stages of 
cell line development (Figure 8). FFPE sections of tumour 
identified a modal MYC signal pattern showing copy 
number gain (3-6 copies) in 69%, c-MYC amplification 
in 11% and diploid MYC signal in 20% of interphase 
cells analysed. Ascites sample contained 14% diploid 
MYC expressing cells. The majority of cells contain 
MYC amplification (82%) with a small number showing 
copy number gains (4%). This finding demonstrates 
heterogeneity between ascites and solid tumour. The 
differences of MYC between NUOC-1-A1 and NUOC-
1-A2 closely relate to the findings from the SNP array. 
Mostly copy number gains were detected in NUOC-1-A1 
(98%), which would be seen as normal copy number in 
the SNP array, in comparison to 100% MYC amplification 
observed in NUOC-1-A2. Also, the results support the 
hypothesis that NUOC-1-A2 forms the major clone, and 
NUOC-1-A1 the minor clone, in the parental cell line. 
No separation of MYC probes was seen in cells with 
increased chromosome numbers, indicating that MYC 
translocation was not present. In cells with amplification, 
the signal patterns suggested the presence of one or more 
homogeneously staining regions. In some cells isolated 
amplification of the 5′ components of the MYC probe set 
were seen suggesting the presence of varied size amplicons.
In vivo tumourigenicity 
Finally, we assessed the potential of in vivo 
growth by injecting tumour cells at intraperitoneal or 
subcutaneous sites in nude mice. No subcutaneous or 
intraperitoneal tumours or ascites formation was observed 
after 100 days (data not shown). 
Figure 5: Representative G-banded metaphase. Arrows indicate the aberrations noted in all metaphases assessed. The result is 
composite of 4 metaphases assessed.
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DISCUSSION
Here we describe the establishment and 
characterization of a novel ovarian cancer cell line 
derived from a chemotherapy naïve patient. Extensive 
characterisation to date and the unique features described 
in this cell line make it a novel tool for ovarian cancer 
research. 
In order to establish new cellular models of ovarian 
cancer, all samples of ovarian tissue were processed 
to derive primary cell cultures as previously described 
[10]. Primary ovarian cultures provide a model which 
better represents the tremendous heterogeneity of 
ovarian cancer, but which have a number of limitations. 
Specifically, primary cultures have a very short life span 
and slow growth, which limits characterisation as well 
as their application in repeat experiments. Of the 156 
primary cultures we have established so far, NUOC-1 is 
the only culture to spontaneously immortalise. NUOC-1 
cells continue to maintain their morphology and epithelial 
marker expression over repeated passages. 
NUOC-1 was derived from ascites of a mixed 
histology tumour. TP53 mutations are reported in the 
majority of HGS ovarian cancer [11], but are rare in 
endometrioid / clear cells cancers. Therefore the TP53 
wildtype genotype of NUOC-1 is consistent with type 
I ovarian cancers. Furthermore, other genes implicated 
in type I ovarian cancer pathogenesis, namely PIK3CA, 
HINF1B, ERBB2 (HER2), AKT1, PPM1D, and ARID1A, 
are also affected by copy number alterations in NUOC-1. 
Therefore, the NUOC-1 cell line is also representative of 
endometrioid / clear cell ovarian carcinoma. Furthermore, 
NUOC-1 represents a useful model for investigations of 
PTEN function, DNA repair as well as hormone receptor 
negative and tyrosine receptor positive phenotypes.  
The results obtained from G-banding karyotype are 
consistent with previously published karyotype studies on 
epithelial ovarian cancer where high genomic instability 
is observed [12]. The heterogeneity of cells observed 
in NUOC-1 better reflects the heterogeneity of ovarian 
cancer that many cell lines which were derived from a 
single clonal population lack. SNP array results provide 
further insight into the extensive genomic alterations 
present in this cell line. Mixed histology tumours are 
common in ovarian cancer. There remains a debate as to 
whether these are monoclonal tumours with heterogeneous 
morphology or truly mixed tumours. Most recent data 
would tend to lean towards a monoclonal origin [13]. 
There is a significant difference in the genomic 
pattern of the two NUOC-1 sub-cultures, and this is 
Figure 6: Copy number profile of chromosome 8 in (A) NUOC-1, (B) NUOC-1-A1 and (C) NUOC-1-A2 cell lines. Each 
SNP marker is represented and aligned to its position on the chromosomes as well as its designated copy number state. An ideogram of 
chromosome 8 is positioned below the SNP marker plots. Red square – location of c-MYC gene.     
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Figure 7: Copy number profiles of NUOC-1-A1 and NUOC-1-A2 cell lines showing Log R ratio and B allele frequency. 
Each SNP marker is represented and aligned to its position on the chromosomes as well as its designated copy number state. Ideograms of 
each chromosome are positioned below the SNP marker plots. (A) ARID1A captured by a large region of copy neutral LOH on chromosome 
1. (B) PIK3CA located in a region of copy neutral LOH. (C) AKT1, captured by a 155Kb amplicon on chr 14. (D) ERBB2 (HER2), captured 
by amplicon of 405Kb on chr 17. (E) PPM1D located in a region of apparent copy neutral LOH. (F) HINF1B, captured by amplicon of 
115Kb on chr 17.
Figure 8: FISH for MYC results for NUOC-1. MYC was assessed in paraffin embedded tumour sample from the patient NUOC-1 
cell line was derived, ascites sample, NUOC-1-A1 and NUOC-1-A2 cells. (A) The percentage of normal, increased chromosome and MYC 
amplified cells is stated. HSR - homogeneously staining regions. (B) FISH immunoflourescent images. The Cytocell MYC ‘breakapart’ 
Probe set was hybridised to nuclei as recommended by the suppliers. Images were taken at 40x magnification. Results are 1. FFPE embedded 
tumour sample, 2. NUOC-1 ascites sample, 3. NUOC-1-A1, 4. NUOC-1-A2.
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different from the parental line. NUOC-1 cells are 
susceptible to changes in copy number across the entire 
genome, and most of these changes were gains rather 
than losses. This instability could give rise to a very 
heterogeneous tumour in many features, including basic 
cell morphology and is perhaps more likely to develop into 
a mixed morphology tumour. An alternative hypothesis 
is that the tumour contains different pre-existing clones 
which have grown into the two subcultures. Although 
the two sub-lines differ from each other and also from 
the parent population they share most of their features. 
Despite several months in culture the two sub-clones 
retain a genetic profile, in terms of both somatic copy 
number alterations and microsatellite repeat length that is 
very similar to the parental cell population from which 
they were derived. The parental population was found to 
be heterogeneous and continuous selection in different 
flasks has led to the outgrowth of two different sub-
clones, with the NUOC-1-A1 sub-clone being derived 
from the major clone in the parent population. Although 
the novel cell lines described here are clearly susceptible 
to the acquisition of somatic copy number alterations, the 
evidence suggests that the cells are sufficiently stable in 
long-term culture to justify their use as an experimental 
model. 
NUOC-1 cells were not able to form xenografts in 
mice which was consistent with the poor clonogenicity on 
plastic and in soft agar. It has been previously suggested 
that cell lines derived from patients with indolent disease 
exhibit low tumourgenicity. This is not the case for the 
NUOC-1 cell line, as the patient from which the cell line 
originated had extremely aggressive disease and lived 
only 52 days post optimal debulking surgery. Whilst the 
inability of NUOC-1 cells to form xenografts limits its 
use in xenograft models, this should not detract from the 
unique phenotype of this cell line.
MATERIALS AND METHODS
Sample and patient data
Ethical approval was granted (12/NW/0202) for the 
collection of ascites from consented patients undergoing 
surgery for ovarian cancer at the Queen Elizabeth 
Hospital, Gateshead, UK. Clinical details were recorded 
and specimens registered and handled in accordance with 
the Human Tissue Act. Samples were assigned a reference 
number to retain anonymity. Histopathology and tumour 
grades were assigned by a pathologist according to the 
International Federation of Gyneacology and Obstetrics 
(FIGO) criteria. Primary cultures were generated and 
maintained as previously described [10]. Briefly 20 ml 
of ascites was added to 20 ml of warmed Sigma RPMI 
1460 HEPES modified culture medium supplemented 
with 20% v/v foetal calf serum and 100 µl/ml penicillin 
and streptomycin in T75 flasks and incubated at 37°C, in 
5% CO2 humidified air. Cells were passaged, frozen and 
thawed as previously described [14].
Cell lines
All cell lines unless stated otherwise were grown 
in RPMI 1640 media supplemented with 10% FBS and 
100 units/ml penicillin/streptomycin incubated at 37°C 
in 5% CO2. A2780, a human ovarian carcinoma cell line 
and CP70, a mismatch repair (MMR) deficient and TP53 
mutant variant of A2780, 5-fold resistant to cisplatin 
relative to the parental A2780, were a kind gift from Prof. 
R. Brown (formerly of the Cancer Research UK Beatson 
Laboratories, Glasgow). The SKOV-3 cell line derived 
from a human ovarian adenocarcinoma, PC3 and LNCAP 
prostate cancer cell lines, MCF7 and MDA-MB-231 breast 
cancer cell lines and Hela is a cervical cancer cell line 
were all purchased from the American Type Tissue Culture 
Collection (ATCC, VA, USA). 
M059J, DNA-PKcs-deficient human glioblastoma 
cells, were grown in DMEM supplemented with 10% FBS, 
100 units/ml penicillin/streptomycin. M059FUS1 (M059J 
transfected with a portion of chromosome 8 carrying the 
DNA-PKcs gene) cells were cultured in full media with 
400 µg/ml G418. Both were purchased from ATCC.  
OSEC2 cells developed at Newcastle University 
from normal ovarian surface epithelium were incubated 
at 33°C.
UWB1-289 is a BRCA1-null human epithelial 
ovarian cancer cell line derived from a high grade serous 
ovarian carcinoma and was cultured in 50% RPMI 
1640 media supplemented with 10% FBS, 100 units/ml 
penicillin/streptomycin and 50% (v/v) MEBM BulletKit 
media (Lonza) supplemented with 10% FBS. UWB1-
289-BRCA1 is derived from UWB1-289 cells in which 
BRCA1 was restored and was cultured in full media with 
400 µg/ml G418; both were obtained from ATCC.
Characterisation
Morphological features were studied under an 
Olympus CK40 inverted microscope at 40 x magnification. 
Images were captured using VisiCam® software (VWR, 
USA).
Immunofluorescence
Standard techniques for immunofluorescence were 
used to stain for pancytokeritin (mouse monoclonal 
anti-pancytokeratin FITC–conjugated antibody, Upstate 
Millipore Corp., USA), EpCAM (mouse monoclonal 
anti-CD326 Alexafluor® 488–conjugated antibody, 
Biolegend, USA), CA125 (mouse monoclonal anti-
CA125 antibody, Abcam, USA, and Alexafluor® 546 goat 
anti-mouse secondary antibody, Invitrogen, USA), MOC-
31 (mouse monoclonal anti-MOC-31 antibody, Dako, 
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Germany, and Alexaflour® 596 goat anti-mouse secondary 
antibody, Invitrogen, USA), D2-40 (mouse monoclonal 
anti-D2-40 antibody, Dako, Germany, and goat anti-mouse 
Alexafluor® 596 secondary antibody, Invitrogen, USA)and 
vimentin (rabbit monoclonal anti-vimentin antibody, clone 
EPR3776, Abcam, USA, and Alexafluor® 488 goat anti-
rabbit secondary antibody, Invitrogen, USA). 
Homologous recombination assay
Cells were seeded onto glass cover slips and treated 
with 2 Gy ionising radiation and rucaparib at 10 µM for 
24 hours to induce DNA damage.  All experiments were 
performed alongside untreated controls with equivalent 
0.1% DMSO. Cells were then fixed and rehydrated prior 
to staining with 1:100 mouse monoclonal anti-γH2AX 
(Upstate, Millipore Corp., USA) and 1:100 goat polyclonal 
anti-Rad51 (Calbiochem, EMD Biosciences, Inc., USA) 
antibodies with appropriate secondary fluorochrome 
conjugated antibodies, as previously described [8]. Image 
J counting software [15, 16] was used to count γH2AX and 
RAD51 nucleic foci. Cells were classed as homologous 
recombination (HR) competent if there was more than a 
2 fold increase in RAD51 foci, after DNA damage was 
confirmed by a 2 fold increase in γH2AX. 
Non homologous end joining assay
Cell extracts were prepared as previously described 
[17] using three T175 flasks for each lysate. Trypsinised 
cells were homogenized in hypotonic buffer (final 
volume 0.5 ml) and mixed with 0.5 vol of high salt 
buffer. Ultracentrifugation (Beckman Optima TL120) 
was performed for 56 min at 70000RPM at 4°C using 
thick-walled polyallomer microfuge tubes in a Beckman 
TLA120.2 rotor to provide a protein extract. Vectors, 
which on digestion with BstXI yielded a 3.2 kb plasmid 
and 1.2 kb λ fragment with either compatible or 2 bp 
incompatible ends provided substrates and controls for 
the NHEJ assay, were kindly donated by Dr Anne Kiltie 
(Oxford, UK). DNA fragments were gel-purified using 
spin columns (Qiagen, UK) and resuspended to 25 ng/μl. 
End-joining reactions (20 μl) were carried out with 45 μg 
protein extract and 50 ng DNA substrate in the presence of 
50 mM HEPES pH 8.0; 40 mM KOAc; 0.5 mMMg(OAc)2; 
1 mM ATP; 1 mM DTT and 0.1 mg/ml BSA at 37°C for 
2.5 hr. Samples were incubated with RNaseA (80 μg/ml) 
for 10 min and then protein was removed by incubation 
with proteinase K (2 mg/ml) and 0.5% (w/v) SDS for 
10 min at 37°C followed by 10 min 55oC and 10 min 
65°C incubation. Plasmid DNA was extracted with Tris-
buffered phenol/chloroform/isoamyl alcohol. Analysis of 
plasmid end joining was performed by agarose (0.7%) gel 
electrophoresis and GelRed (VWR) staining. Images were 
collected and quantified using G-BOX. 
Sulforhodamine B (SRB) assay
A routine sulforhodamine B (SRB) assay 
was used to assess cytotoxicity and cell growth as 
previously described [18]. Briefly, cells were seeded 
at a concentration of 1000 cells/well of a 96-well plate 
and after adherence, treated with various concentrations 
of inhibitors for 10 days before fixation, staining and 
spectrophotometer assessment. Inhibitors used were 
cisplatin, paclitaxel, camptothecin, doxorubicin, rucaparib 
(donation from Clovis), Nutlin3 and irradiation (in house 
D3300 X-ray system). For assessment of growth, cells 
were fixed daily for 14 days and the doubling time was 
calculated according to the slope of the linear portion of 
the growth curve. 
Colony formation assays 
50,000 cells/well were seeded in a 6 well plate for 
24 hours. Cells were then incubated for 24 hours with 
various concentrations of the cytotoxic agent before 
reseeding at concentrations of 2,500, 5,000 and 10,000 
cells for each drug treatment. Cells were incubated at 
37°C for 30 days. The medium was aspirated, plates were 
washed in PBS and then fixed using Carnoy’s fixative 
(acetic acid: methanol 1:3 v/v) followed by staining with 
1% crystal violet. 
In vivo growth in SCID mice
All animal studies were performed in compliance 
with the UK Home Office Animals (Scientific Procedures) 
Act 1986 for the use of animals in scientific procedures 
and have undergone local ethical review. Project licence 
number PPL 60/42222. The tumorigenic potential of cell 
line was assessed based on their ability to form tumours in 
8–10 week old female nude SCID mice at subcutaneous 
(s.c.) right gluteal or intraperitoneal (i.p.) injection sites 
(cells were first labelled by transfection with a luciferase 
containing vector, which was kindly gifted by Dr A Elder 
[Newcastle upon Tyne, UK]). Five mice were transplanted 
with 5 × 106 cells suspended in 50% medium / 50% v/v 
matrigel subcutaneously and five mice were transplanted 
with luciferase-expressing 5 × 106 cells suspended in 
phosphate buffered saline (PBS) for i.p. injections. 
The animals were housed under sterile conditions in a 
laminar flow environment with unrestricted access to food 
and water. Tumour formation was assessed by observation 
of subcutaneously implanted mice for 100 days. The five 
i.p transplanted mice underwent non-invasive whole-body 
imaging starting at 0, 10 and 30 days after implantation using 
the IVIS Spectrum Imaging system (Caliper Life Sciences, 
Hopkington, MA, USA). Mice were injected i.p. with 3 mg/
mouse D- luciferin (Promega) solution ten minutes before 
being anaesthetized for the imaging procedure. Photon 
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emission was captured and expressed in p/s/cm2/sr using 
Living Image software (Version 4.3.1., Caliper Life Sciences).
Western blotting
Cells were lysed using Merck phosphosafe buffer 
(Calbiochem) and protein concentration was quantified 
using a Pierce protein assay (ThermoScientific) as per 
manufacturer’s instructions. Samples were denatured 
at 100°C for 10 minutes before separation of protein 
in the cytosolic extracts according to size using SDS-
PAGE gel electrophoresis. Proteins were transferred 
electrophoretically from the gels onto a nitrocellulose 
membrane (Hybond C Membrane (GE Healthcare). 
Antibodies used for detection of protein were: Oestogen 
receptor a 1:1000 (Santa Cruz 8005), Progesterone 
receptor 1:1000 (Cell signalling), Androgen receptor 
1:1000 (Santa Cruz 7305), HER-2 1:1000 (Santa Cruz 
33684), HER-3 1:1000 (Santa Cruz 285), MDM2 
3:1000 (Calbiochem), p53 2:1000 (Vector), p21 1:100 
(Calbiochem), GAPDH 1:3000 (Santa Cruz) and Actin 
1:1000 (Sigma). 
Mutation analyses
TP53 mutations were detected by Sanger dideoxy 
DNA sequencing. Polymerase chain reaction (PCR) 
was used to amplify exons 3–9 of the TP53 gene in 
GeneAmp PCR System 9700 (Applied Biosystems). PCR 
was performed in a 25 μl volume containing 200 ng of 
DNA; 1 × PCR Gold buffer (New England BioLabs); 
2.5 nmol each dNTP, 1.5 mM MgCl2; 15 pmol of each 
primer (Sigma-Aldrich); and 1.25 U of Amplitaq Gold 
(New England BioLabs). The PCR conditions were 5 
min at 95°C, 40 cycles (30 s 94°C, 30 s 55–60°C, 30 s 
72°C). PCR products were then purified according to 
the manufacturer’s instructions using a PureLink PCR 
Purification Kit (Invitrogen, Cat no: K3100-01/-02). 
Mutations were confirmed by sequence analysis by DBS 
Genomics (Durham University, UK). Sequencing results 
were analysed using the SeqMan software package (DNA 
star). 
Next-generation sequencing
Genomic DNA extracted from cancer cells 
cultured from NUOC-1 was sheared to a mean length 
of 500 bp using nitrogen nebulisation. A custom-made 
NimblegenSeqCap EZ library (Nimblegen, Madison, WI, 
USA) was used to enrich for the sequence of interest. 
This comprised the exonic regions of > 180 DNA repair 
genes and limited intronic material. Captured sequence 
was subjected to massively parallel next-generation DNA 
sequencing by using the Roche 454 GS FLX platform 
(454 Life Science, Branford, CT, USA). A bespoke 
analysis pipeline was used to identify pathogenic changes 
and potential variants of interest (single nucleotide 
polymorphisms with < 1% population prevalence) across 
the target genes. 
STR profiling
STR profiling was perfomed by NewGene 
Limited. Briefly  eight short tandem repeat (STR) loci, 
plus Amelogenin, were amplified using the GenePrint® 
10 System, supplied by Promega. The reaction products 
were processed using an Applied Biosystems® 3130 × l 
Genetic Analyzer and the resulting data interpreted 
using GeneMarker® v2.6.0 software (SoftGene LLC). 
Appropriate positive and negative controls were included 
in every batch of samples analysed.
SNP array copy number analysis
For SNP array analysis DNA was extracted using 
a QIAmp DNA Kit (Qiagen) as per the manufacturer’s 
instructions. Intra-chromosomal copy number alterations 
were determined using data derived from NUOC-
1-A1 and NUOC-1-A2 cell lines genotyped using the 
OmniExpressExome BeadChip from Illumina (San Diego, 
California). Copy number variation data was analysed 
using cnvPartition v.3.2.0 in GenomeStudio V2011.1 
(Illumina), with deviations from copy neutral called if 
affecting 10 or more markers and achieving a confidence 
threshold score of at least 50. Alterations affecting the 
X chromosome and all 22 autosomal chromosomes 
were characterised. Deviations from copy neutral called 
by cnvPartition were confirmed manually (It should be 
noted that copy neutral equates to a copy number of 4 for 
NOUC-1, NUOC-1-A1 and NUOC-1-A2 because these 
cell lines are predominantly tetraploid, as determined 
by G-banding karyotyping (Figure 5)). A small number 
of additional copy number alterations not identified by 
cnvPartition were identified manually. Regions of copy 
neutral loss of heterozygosity (LOH) exceeding 10 Mb 
were also identified manually.
Parental NUOC-1 cells were also genotyped using 
the OmniExpressExome BeadChip and the resulting data 
visualised using GenomeStudio V2011.1. These data were 
manually interrogated to confirm whether copy number 
alterations and regions of copy neutral LOH identified 
in NUO-C1-A1 and NUOC-1-A2 were also visible in 
parental NUOC-1 cells. Regions of copy number alteration 
and copy neutral LOH identified in NUOC-1-A1, 
NUOC-1-A2 and parental NUOC-1 cells are detailed in 
Supplementary Table 2.
G-band karyotyping 
Karyotyping was performed by the Cancer 
Cytogenetics department at Newcastle Hospitals NHS 
Foundation Trust, according to established protocols. 
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Metaphase chromosome spreads were prepared by 
incubating proliferating cells with 100  ng/ml colcemid for 
4  h followed by resuspension in 75  mM KCl for 7  min. 
Cells were fixed by resuspension in 3:1 methanol:acetic 
acid before karyotyping. Slide-fixed cells were incubated 
overnight at 60°C and G-banded by standard trypsin and 
Giemsa methods. Four metaphase chromosome spreads were 
analysed for each population and the karyotypes recorded.
Fluorescence in Situ Hybridization for c-MYC  
FISH analysis was performed by the Cancer 
Cytogenetics department at Newcastle Hospitals NHS 
Foundation Trust, according to established protocols. The 
Cytocell MYC ‘breakapart’ Probe set was hybridised to 
nuclei as recommended by the suppliers. Slides were heated 
to 72°C for 5 min and then incubated for 24  hr at 37°C 
in a humidified hybridisation chamber (HYBrite; Abbott 
Molecular). After hybridisation, slides were counterstained 
with 4′,6-diamidino-2-phenylindole (Vector Laboratories, 
Peterborough, UK). FISH was scored with an Olympus 
BX-61 fluorescence microscope (Olympus, Southend-on-
Sea, UK) with a × 100 oil objective. Images were analysed 
using the CytoVision 7.2 SPOT counting system (Leica 
Microsystems, Gateshead, UK). A minimum of 100 nuclei 
were scored per test by two independent analysts.
ACKNOWLEDGMENTS 
We gratefully acknowledge the generosity and co-
operation of the patients who donated their tissue and 
the support of clinical staff at Northern Gynaecological 
Oncology Centre, Queen Elizabeth Hospital, Gateshead, 
UK. This work was funded by Cancer research UK and The 
Newcastle Healthcare Charity and Newcastle upon Tyne 
NHS Charity, to whom we are most grateful. Many thanks to 
Dr Alex Elder (Newcastle upon Tyne, UK) for kind donation 
of luciferase vector for the study of tumourgenecity. To Dr 
Anne Kiltie (Oxford, UK) for donation of vectors for the 
study of NHEJ in NUOC-1. And to Mrs Angharad Goodman 
for contribution to FISH analysis. 
CONFLICTS OF INTEREST
Authors have no conflicts of interest to disclose.
GRANT SUPPORT 
This project was funded by CRUK grant: 
RES/0190/7578.
REFERENCES
1. Statistics NOf. Mortality statistics: Deaths registered in 2010 
(Series DR) Table 5.2. National Office for Statistics). 2011.
 2. Parmar MK, Ledermann JA, Colombo N, du Bois A, 
Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, 
Torri V, Floriani I, Jayson G, Lamont A, et al. Paclitaxel 
plus platinum-based chemotherapy versus conventional 
platinum-based chemotherapy in women with relapsed 
ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 
2003; 361:2099–2106.
 3. Auersperg N, Maines-Bandiera SL, Dyck HG, Kruk PA. 
Characterization of cultured human ovarian surface 
epithelial cells: phenotypic plasticity and premalignant 
changes. Lab Invest. 1994; 71:510–518.
 4. Nitta M, Katabuchi H, Ohtake H, Tashiro H, Yamaizumi M, 
Okamura H. Characterization and tumorigenicity of human 
ovarian surface epithelial cells immortalized by SV40 large 
T antigen. Gyn Onc. 2001; 81:10–17.
 5. Shenhua X, Lijuan Q, Hanzhou N, Xinghao N, Chihong Z, 
Gu Z, Weifang D, Yongliang G. Establishment of a highly 
metastatic human ovarian cancer cell line (HO-8910PM) 
and its characterization. J Exp Clin Cancer Res. 1999; 
18:233–239.
 6. Yabushita H, Ueno N, Sawaguchi K, Higuchi K, 
Noguchi M, Ishihara M. Establishment and characterization 
of a new human cell-line (AMOC-2) derived from a serous 
adenocarcinoma of ovary. Nihon Sanka Fujinka Gakkai 
zasshi. 1989; 41:888–894.
 7. Korch C, Spillman MA, Jackson TA, Jacobsen BM, Murphy 
SK, Lessey BA, Jordan VC, Bradford AP. DNA profiling 
analysis of endometrial and ovarian cell lines reveals 
misidentification, redundancy and contamination. Gyn Onc. 
2012; 127:241–248.
 8. Mukhopadhyay A, Elattar A, Cerbinskaite A, Wilkinson SJ, 
Drew Y, Kyle S, Los G, Hostomsky Z, Edmondson RJ, 
Curtin NJ. Development of a functional assay for 
homologous recombination status in primary cultures of 
epithelial ovarian tumor and correlation with sensitivity to 
poly (ADP-ribose) polymerase inhibitors. Clin Can Res. 
2010; 16:2344–2351.
 9. Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, 
Kyle S, Mukhopadhyay A, Los G, Hostomsky Z, 
Plummer ER, Edmondson RJ, Curtin NJ. Therapeutic 
potential of poly(ADP-ribose) polymerase inhibitor 
AG014699 in human cancers with mutated or methylated 
BRCA1 or BRCA2. J Natl Cancer Inst. 2011; 103:334–346.
10. O Donnell RL, McCormick A, Mukhopadhyay A, 
Woodhouse LC, Moat M, Grundy A, Dixon M, Kaufman A, 
Soohoo S, Elattar A, Curtin NJ, Edmondson RJ. The use 
of ovarian cancer cells from patients undergoing surgery to 
generate primary cultures capable of undergoing functional 
analysis. PLos One. 2014; 9:e90604.
11. Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, 
Riad M, Sharma R, Stewart C, Fereday S, Caldas C, 
Defazio A, Bowtell D, Brenton JD. Driver mutations in 
TP53 are ubiquitous in high grade serous carcinoma of the 
ovary. J Path. 2010; 221:49–56.
Oncotarget26844www.impactjournals.com/oncotarget
12. Gorringe KL, Campbell IG. Large-scale genomic analysis 
of ovarian carcinomas. Mol Oncol. 2009; 3:157–164.
13. Mackenzie R, Talhouk A, Eshragh S, Lau S, Cheung D, 
Chow C, Le N, Cook LS, Wilkinson N, McDermott J, 
Singh N, Kommoss F, Pfisterer J, et al. Morphologic and 
Molecular Characteristics of Mixed Epithelial Ovarian 
Cancers. Am J Surg Path. 2015; 39:1548–1557.
14. Maloney KE, Norman RW, Lee CL, Millard OH, Welch JP. 
Cytogenetic abnormalities associated with renal cell 
carcinoma. J Urol. 1991; 146:692–696.
15. Abramoff  M, Magelhaes, P., Ram, S. Image processing 
with ImageJ. Biophoton Int. 2004; 11:36–42.
16. Znojek P. PhD Thesis. Newcastle University. 2011.
17. Diggle CP, Bentley J, Kiltie AE. Development of a rapid, 
small-scale DNA repair assay for use on clinical samples. 
Nucleic Acids Res. 2003; 31:e83.
18. Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay 
for cytotoxicity screening. Nat Protoc. 2006; 1:1112–1116.
